Comparison of Alpinia officinarum Hance and placebo on spermogram test

Comparison of Alpinia officinarum Hance and placebo in men with abnormal semen sperm

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016103130616N1

Enrollment

Registered

2017-02-10

Start date

2017-02-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sperm disorders. Disorder of male genital organs, unspecified

Interventions

Intervention 1: In the intervention group, 3 grams of Alpinia officinarum Hance powder in will administer in 1-gram capsules per day For three months. Intervention 2: The control group, 3 grams of pla

Treatment - Drugs

Placebo

In the intervention group, 3 grams of Alpinia officinarum Hance powder in will administer in 1-gram capsules per day For three months.

The control group, 3 grams of placebo capsules (sucrose) will receive on a daily for three months

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Inclusion criteria : idiopathic oligospermia disorder; idiopathic Teratospermic disorder; idiopathic Asthenospermia disorder

Exclusion criteria

Exclusion criteria: Exclusion criteria:azoospermia; Pretesticular disorder such as endocrine disorders (hyperprolactinemia, congenital adrenal hyperplasia, ...); Chromosomal disorders such as Klinefelter, men XX, XYY; known Testicular dysfunction such as varicocele or orchitis or Cryptorchidism; Post testicular dysfunction such as the mechanical obstruction, impaired embryo transfer or functional obstruction, vasectomy and; A history of treatment for infertility in the past three month; Medication history affecting semen; History of anti-metabolite drugs ;Diabetics patients; Hypo-and hyperthyroidism patients; History of chemotherapy; A history of cerebrovascular diseases ; A history of exposure to radiation or radioactive radiation

Design outcomes

Primary

Measure	Time frame
Sperm motility. Timepoint: Before the treatment & Three months after taking the drug and placebo. Method of measurement: spermogram.;Sperm morphology. Timepoint: Before the treatment & Three months after taking the drug and placebo. Method of measurement: spermogram.;Sperm Count. Timepoint: Before the treatment& Three months after taking the drug and placebo. Method of measurement: spermogram.;Sperm volume. Timepoint: Before the treatment. Method of measurement: spermogram.	—

Measure

Time frame

Sperm motility. Timepoint: Before the treatment & Three months after taking the drug and placebo. Method of measurement: spermogram.;Sperm morphology. Timepoint: Before the treatment & Three months after taking the drug and placebo. Method of measurement: spermogram.;Sperm Count. Timepoint: Before the treatment& Three months after taking the drug and placebo. Method of measurement: spermogram.;Sperm volume. Timepoint: Before the treatment. Method of measurement: spermogram.

—

Secondary

Measure	Time frame
Volume of semen. Timepoint: Three months after taking the drug and placebo. Method of measurement: spermogram.;Sperm Count. Timepoint: Three months after taking the drug and placebo. Method of measurement: spermogram.;Sperm motility. Timepoint: Three months after taking the drug and placebo. Method of measurement: spermogram.;Sperm morphology. Timepoint: Three months after taking the drug and placebo. Method of measurement: spermogram.	—

Measure

Time frame

Volume of semen. Timepoint: Three months after taking the drug and placebo. Method of measurement: spermogram.;Sperm Count. Timepoint: Three months after taking the drug and placebo. Method of measurement: spermogram.;Sperm motility. Timepoint: Three months after taking the drug and placebo. Method of measurement: spermogram.;Sperm morphology. Timepoint: Three months after taking the drug and placebo. Method of measurement: spermogram.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZahra Memariani

Babol University of Medical Sciences

z.memariani@mubabol.ac.ir+98 11 3219 4730

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026